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DEPRESSION of the haemopoietic system with leucopenia and thrombocyto-
penia is a well-recognised hazard of the use of antimitotic agents in the treatment
of malignant disease. During a study of the causes of thrombocytosis, however,
we observed that a rise in the platelet count appeared to be frequent following
methotrexate therapy. We report our findings on the effect of methotrexate on
the platelet count, and, in particular, on its effect in producing a thrombocytosis.
PATIENTS AND METHODS
The case records of 39 patients who had received methotrexate (amethopterin)
as therapy for malignant disease were examined. Serial platelet counts were
performed, at intervals of not more than 3 days, before, throughout, and after
the period of therapy.
Methotrexate was administered by intra-arterial infusion after cannulation of
the regional artery supplying the site of the tumour (18 patients) by intravenous
injections (19 patients) or orally (2 patients). The total methotrexate dose by
intra-arterial infusion ranged from 150 mg. to 640 mg. given over a period of 3
to 16 days, mean 7.0 days; by the intravenous route, 15 mg. to 150 mg. over
3-27 days, mean 8.5 days; and the oral dosages were 70 mg. and 110 mg., over 15
and 25 days, respectively. The length of therapy exceeded 10 days in only 9
patients.
The malignant conditions treated were carcinomas of breast (13); mouth,
fauces or tongue (7); larynx (4); skin (4); oesophagus (3); vulva (3); jaw (2);
parotid gland (1); bronchus (1); ear (1). Although many patients had recurrent
carcinomas, especially of the squamous epithelial type, none had evidence of
disseminated disease beyond the regional lymph nodes clinically, and none had a
leucoerythroblastic blood picture before therapy. Bone-marrow biopsy was not
carried out as a routine procedure.
Platelet counts were performed by the method of Oettle and Spriggs (1951).
The normal range of the platelet count in our laboratory is 150-270,000 c.mm.
RESULTS
Phase of thrombocytopenia-Table I shows that a reduction in the platelet
count ofmore than 25% ofthe pre-treatment level occurred in 31 ofthe 39patients.
It is also apparent that the platelet count fell slightly earlier after both the start
and the end of the course of intra-arterial, than after intravenous, administration
of methotrexate, presumably because of the higher dosage in the intra-arterial
treated group.METHOTREXATE AND PLATELETS
TABLE I.-Fall in the Platelet Count with Methotrexate Therapy
Maximum fall in platelet count, as %
of pre-treatment count
Time of maximum fall in groups (b),
(c) and (d) from start of therapy
(days)
Time of maximum fall in groups (b),
(c) and (d) from end of therapy
(days)
(a) Less than 25%
(b) 25-49%
(c) 50-74%
(d) More than 75%
7-10
11-14
15-18
Before end of therapy
0-3
4-7
8-11
Mode of administration
r
A
Intra- Intra-
arterial venous Oral Total
Number ofpatients r I
4 3 1 8
5 4 1 10
5 8 13
4 4 8
8
5
1
1
7
8
1 1
7 2
6 10
- 3
1
1
9
12
10
2
10
16
3
Phase of thrombocytosis.-After the period when the majority of patients
showed thrombocytopenia, a rise in the platelet count of over 25% above the
pre-treatment level was observed in 37 of the 39 subjects studied (Fig. 1). In 29
ofthese, this rise followed a fall in the platelet count of at least 25% ofthe initial
level. In 25 patients the maximum platelet count exceeded 500,000 c.mm. It
is evident from Table II that the peak of this thrombocytosis occurs at a fairly
constant time after the start of therapy, the end of therapy, and the minimum
platelet count, with both intra-arterial and intravenous therapy.
The rise in the platelet count bore no relationship to recognised intercurrent
infection, or to operative procedures during the period of study. Twenty-two
patients had started radiotherapy before the maximum platelet count, but the
time between the start of radiotherapy and the maximum platelet count varied
TABLE II.-Rise in the Platelet Count After Methotrexate
Mode of administration
All patients with rise in platelet count .
Time between start of therapy and .
maximum platelet count (days)
Time between end of therapy and
maximum platelet count (days)
Patients with fall in platelet count
followed by rise
Time between minimum and maxi-
mum platelet counts (days)
Intra- Intra-
arterial venous Oral Total
Nuimber ofpatients
18 18 1 37
Less than 15
15-18
19-22
23-26
More than 27
On therapy
Less than 10
10-13
14-17
18-21
3-6
7-10
11-14
1
4 1
12 9
2 2
- 5
1
7
9
1
14
10
4
1
- 5
1 22
4
- 5
1
6
10
2
15
2
10
3
1
1
13
19
3
- 29
2
20
7
23
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from 1 to 18 days, and radiotherapy did not appear to influence the extent or
timing of the thrombocytosis.
Eighteen patients with a rise in the platelet count of over 50% had serial
counts continued long enough to allow assessment ofthe period ofthrombocytosis.
Twelve ofthese patients started radiotherapy, either before the peak ofthe plate-
let count, or before its fall to around the initial level. This did not substantially
1000
900
800
700
U E
E
1-f
i 600
x
Z 500 oo 0
u
I--
400
-1 0.
300
200
100
0 5 10 15 20 25 30
DAYS AFTER START OF METHOTREXATE
Fia. I.-Pre-treatment, minimum and maximum platelet counts after start of
methotrexate therapy.
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reduce the duration of thrombocytosis, the mean period of an increased platelet
count being 12.8 days in the 12 patients, compared with 13.5 days in the 6 patients
not having radiotherapy. Table III shows the lack of correlation between the
extent and duration ofthe rise in platelet count.
TABLE III.-Length ofPeriod ofIncreased Platelet Count
Maximum rise in platelet count Mean period of increased
(% of pre-treatment count) Number of patients platelet count (days)
50-99% 4 . 12.3
100-199% 9 . 129
More than 200% . 5 . 14-0
Changes in the leucocyte count
Twenty-five ofthe 39 patients developed leucopenia (fall in the W.B.C. count to
below 3,500 c.mm.) during or following methotrexate therapy. The time for the
maximum fall in the leucocyte count showed greater variation than that for
platelets, but the majority occurred in the same time period; 7 to 16 days after
the start of therapy. Nineteen ofthe 25 leucopenic patients had a fall in platelet
count to below 100,000 c.mm., and 23 had a reduction in the platelet count
exceeding 25%.
The records were examined to determine whether a leucocytosis developed in
conjunction with a rise in the platelet count. Twelve patients had a W.B.C.
count exceeding 10,000 c.mm., but the time when this occurred ranged from one
to 44 days after the start of therapy, and in the majority, the rise was clearly
related to infection or an operative procedure. There was no relationship between
the timing of the leucocytosis and that of the thrombocytosis.
Changes in the platelet countfollowing other anti-mitotic agents
The records of 8 patients who had serial platelet counts following anti-mitotic
therapy other than methotrexate were examined. Six had a reduction in the
platelet count exceeding 25% and 5 had a later rise in the platelet count exceeding
25% of the pre-treatment level. The pre-treatment, minimum and maximum
counts in the 8 patients are shown in Fig. 2. It can be seen that the majority
had the same sequence as observed for methotrexate, but the changes were less
consistent, and tended to occur earlier.
DISCUSSION
We have shown that the administration of therapeutic doses of methotrexate
is followed, in the majority ofpatients, by a reduction in the platelet count with a
subsequent thrombocytosis; this latter change has not been reported previously
in relation to anti-mitotic therapy, though the occurrence of thrombocytosis in
malignant disease is well documented (Levin and Conley, 1964). Whether the
thrombocytosis is an effect of methotrexate per se or a response to a period of
thrombocytopenia is not clear. It seems unlikely that a marrow-depressing drug
should cause delayed stimulation of one of the marrow elements; a " rebound "
phenomenon following thrombocytopenia appears to be a more satisfactory
explanation. However, some patients developed thrombocytosis in the absence
ofan observed preceding thrombocytopenia, and there was norelationship between
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FIG. 2.-Pre-treatment, minimum and maximum platelet counts after start of anti-mitotic therapy-
the severity of the thrombocytopenia and the extent of the succeeding thrombo-
cytosis, but it is possible that a very transient phase of thrombocytopenia was
missed in some patients. While few patients treated with other anti-mitotic
drugs had platelet counts performed for a sufficiently long period after cessation
oftherapy to determine whether the same sequence occurs as after methotrexate,
the findings in the small number of patients studied suggest that the production
ofthrombocytopenia followedby athrombocytosis is not confined to methotrexate.
It is recognised that replacement therapy for vitamin B12 and folic acid defi-
ciency states may be accompanied by a thrombocytosis and it is possible that
cessation of treatment with a folic acid antagonist produces the same change.
There is now, however, considerable evidence that, under certain circumstances,
human plasma contains a substance (" thrombopoietin ") capable of promoting
platelet production (Schulman et al., 1960). Removal or destruction of platelets
in the rat stimulates increased platelet production with a subsequent rise in the
platelet count to above the initial level (Matter et al., 1960) and it has been
suggested that this is mediated through the release of " thrombopoietin "
(de Gabriele and Pennington, 1967). It seems likely that the thrombocytosis
following methotrexate therapy is due to the release of " thrombopoietin " during
the period ofthrombocytopenia rather than to a specific effect ofmethotrexate.
SUMMARY
The thrombocytopenia resulting from methotrexate therapy is frequently
followed by a thrombocytosis. It is postulated that the thrombocytosis is due
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to non-specific stimulation ofplatelet production resulting from thrombocytopenia
rather than to a specific effect ofmethotrexate per 8e.
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